MedTrace Logo

The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV

NCT05690802 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1060

Last updated 2023-01-19

No results posted yet for this study

Summary

To observe and evaluate the safety and effectiveness of Palonosetron hydrochloride capsule in preventing acute nausea and vomiting caused by moderate emetic chemotherapy; The characteristics of the applicable population, clinical medication and clinical benefits of Palonosetron Hydrochloride Capsules were analyzed.

Conditions

  • Nausea and Vomiting

Interventions

DRUG

Palonosetron hydrochloride capsules

This protocol only stipulates "Palonosetron capsule containing hydrochloric acid protocol", and does not make uniform provisions on the treatment course, and does not interfere with the actual clinical usage and dosage.

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Liu Hong, master · Air Force Military Medical University, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-16
Primary Completion
2027-05-30
Completion
2029-05-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05690802 on ClinicalTrials.gov